BioBusiness sales were 5% lower in DKK and 12% lower in LCY compared to 2009. Divestment of noncore activities in the microorganism business in 2009 and lower sales of biopharmaceutical ingredients (BPI) were the main reasons for the decrease. Organically, BioBusiness sales were 10% lower compared to 2009.
Biopharmaceutical ingredient sales were down by 21% in DKK and by 28% in LCY compared to 2009. The decrease was caused by lower sales of Recombumin® and cell culture ingredients throughout the year and also by the absence of plectasin sales in the fourth quarter of 2010 compared to the same quarter of 2009. The BPI industry is subject to substantial quarterly variations in sales patterns, as sales comprise a small number of transactions of relatively large value.